|10th December 2020||Stacey M Stevens||20,000||Open or private sale||$13.00||$260,000.00|
|8th December 2020||R. Scott Areglado||15,000||Exercise of derivative||$6.00||$90,000.00|
|8th December 2020||R. Scott Areglado||15,000||Open or private sale||$12.00||$180,000.00|
|4th December 2020||Stacey M Stevens||18,665||Open or private sale||$11.28||$210,481.47|
|4th December 2020||Stacey M Stevens||18,665||Exercise of derivative||$6.68||$124,682.20|
|3rd December 2020||Stacey M Stevens||1,100||Open or private sale||$11.07||$12,180.96|
|3rd December 2020||Stacey M Stevens||1,100||Exercise of derivative||$6.68||$7,348.00|
|8th October 2020||Stacey M Stevens||15,873||Exercise of derivative||$2.27||$36,031.71|
|8th October 2020||Stacey M Stevens||15,873||Open or private sale||$10.00||$158,730.00|
|9th September 2020||Andy Sassine||10,000||Open or private sale||$9.47||$94,746.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
iCAD, Inc. engages in the provision of advanced image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer. It operates through the Cancer Detection and Cancer Therapy business segments. The company was founded in 1984 and is headquartered in Nashua, NH.